Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-014762
Filing Date
2024-11-07
Accepted
2024-11-07 08:07:49
Documents
53
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ewtx-20240930x10q.htm   iXBRL 10-Q 2030940
2 EX-31.1 ewtx-20240930xex31d1.htm EX-31.1 19406
3 EX-31.2 ewtx-20240930xex31d2.htm EX-31.2 19219
4 EX-32.1 ewtx-20240930xex32d1.htm EX-32.1 7618
5 EX-32.2 ewtx-20240930xex32d2.htm EX-32.2 7541
  Complete submission text file 0001558370-24-014762.txt   6102002

Data Files

Seq Description Document Type Size
6 EX-101.SCH ewtx-20240930.xsd EX-101.SCH 28460
7 EX-101.CAL ewtx-20240930_cal.xml EX-101.CAL 31589
8 EX-101.DEF ewtx-20240930_def.xml EX-101.DEF 111993
9 EX-101.LAB ewtx-20240930_lab.xml EX-101.LAB 289407
10 EX-101.PRE ewtx-20240930_pre.xml EX-101.PRE 209866
56 EXTRACTED XBRL INSTANCE DOCUMENT ewtx-20240930x10q_htm.xml XML 909263
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40236 | Film No.: 241433298
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)